Pharmacyclics Inc (PCYC)

PCYC (NASDAQ:Drugs) EQUITY
$255.95
neg -0.48
-0.19%
Today's Range: 255.50 - 256.83 | PCYC Avg Daily Volume: 1,617,600
Last Update: 03/31/15 - 4:00 PM EDT
Volume: 824,704
YTD Performance: 109.74%
Open: $256.45
Previous Close: $256.43
52 Week Range: $82.51 - $258.95
Oustanding Shares: 76,016,912
Market Cap: 19,502,518,858
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 7 9 10
Moderate Buy 0 0 0 0
Hold 11 7 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.69 2.00 1.71 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 233.23
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
233.23 232.80 27.35
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
109.19% 155.18% 823.74%
GROWTH 12 Mo 3 Yr CAGR
Revenue 180.50 87.63 3.39
Net Income 28.50 -3.45 0.00
EPS 26.80 -2.93 0.00
Earnings for PCYC:
EBITDA 0.13B
Revenue 0.73B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.07 $-0.49 $0.26 $4.51
Number of Analysts 8 8 10 9
High Estimate $0.25 $0.43 $1.76 $7.96
Low Estimate $-0.21 $-1.36 $-1.24 $2.07
Prior Year $0.23 $-0.49 $1.09 $0.26
Growth Rate (Year over Year) -69.02% -0.26% -75.78% 1,607.91%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Here are healthcare stocks of all shares and sizes with strong charts.
Combined Heinz-Kraft heads a long second-quarter list.
You can't help but feel better about both groups.
If there is no catalyst, I'd join those who sell on a bounce.
This sector could see some real damage.
Own them, or take something off the table?
Market backtracks on skepticism over biotechs.
These companies are doing great -- take some profits!
It shouldn't be possible, but it never seems too late to get in.

Jobs Report and Biotech Nerves Real Money Pro($)

I am happy to be standing in for Doug Kass today on the Daily Diary.

Columnist Conversations

The cluster of high wick candles that formed in February and early this month may have been a tell, but Linded...
When the tide goes out is when we will find out how ugly things really are. The waters are getting more turbul...
Market ends the month and the quarter on a down note. Indices are largely flat for 2015, in the weakest openi...
Micron is holding a key support zone ahead of Thursday afternoon's Q2 earnings report. Today the stock i...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.